Baitouweng Tang originates from Zhang Zhongjing’s Shanghan Lun, a classical medical text, and combines four herbs: Pulsatilla chinensis (Bai Tou Weng), Phellodendron chinense (Huang Bai), Coptis chinensis (Huang Lian), and Fraxinus chinensis (Qin Pi). The formula is traditionally used to cool the blood and stop diarrhea, and it remains a representative treatment for febrile dysentery and various gastrointestinal disorders. Despite its long clinical history, the precise pharmacodynamic pathways remained incompletely characterized. The new study, published in Food Science & Nutrition, set out to determine whether the formula works by regulating intestinal microbiota and related tryptophan metabolism to activate the aryl hydrocarbon receptor, a key signaling molecule in gut immunity.

The researchers prepared the formula by refluxing the four herbs in distilled water in a 4:3:2:4 ratio, then analyzed its chemical constituents using UHPLC-HRMS. The analysis identified alkaloids, phenylpropanoids, sugars and glycosides, terpenoids, and organic acids, with alkaloids, phenylpropanoids, and terpenoids as the main categories. Among the more abundant components were Pulsatilla saponin D, Pulchinenoside B, 23-hydroxybetulinic acid, oleanolic acid, berberine, oxyberberine, 8-oxocoptisine, obacunone, esculin, esculetin, and fraxetin, each characterized by retention time, molecular formula, and fragment ions.

To test the formula’s effects, the team induced acute colitis in C57BL/6 mice with 2.5% dextran sulfate sodium and administered Baitouweng Tang at high, medium, and low doses of 8.1, 5.4, and 2.7 g/kg, alongside a salazosulfapyridine positive control. The colitis mice lost weight, showed elevated disease activity index scores, and had shortened colons. Treatment with the formula and the positive drug inhibited weight loss, reduced DAI scores, and curbed colon shortening to varying degrees. Molecular analysis revealed that colitis elevated Ifn-γ and Il-6 mRNA levels in colon tissue, while the formula and positive drug diminished these inflammatory markers and differentially elevated Il-22 mRNA expression, indicating a fine protective effect on colitis mice.

Sequencing of the V3-V4 variable region of the 16S rRNA gene showed that colitis markedly shifted the gut microbiota, with the model group diverging from controls in both alpha and beta diversity. At the phylum level, colitis increased Bacteroidetes, Proteobacteria, and Desulfobacterota while Firmicutes declined, a pattern the formula efficiently reversed. At the genus level, the model group showed notable increases in Bacteroides, norank_f_Desulfovibrionaceae, and Alistipes, while Bifidobacterium and Dubosiella declined. The formula boosted Bifidobacterium, Turicibacter, Dubosiella, and Alistipes, suggesting a global regulation of the entire intestinal microecosystem rather than a single-taxon effect.

The critical experiment came next: the researchers depleted the gut microbiota with a mixture of vancomycin, ampicillin, metronidazole, and neomycin sulfate for ten consecutive days, creating a pseudo-germ-free mouse model. Sequencing confirmed that antibiotic treatment collapsed alpha diversity and left only Proteobacteria at the phylum level, with only Enterobacter and Escherichia-Shigella at the genus level. When colitis was induced in these microbe-depleted mice, the beneficial effect of Baitouweng Tang was almost completely attenuated, and tryptophan metabolism was blocked, severely inhibiting AhR signaling activation. This demonstrated that the formula depends on intestinal microbes to exert its anti-colitis effect.

To confirm the microbial contribution, the team performed fecal microbiota transplantation from formula-treated donors into antibiotic-depleted recipient mice. Transplantation partially restored the protective effects, improving body weight and DAI scores, reducing inflammatory infiltration and mucosal damage, restoring colon tissue structure and goblet cell numbers, and suppressing Ifn-γ and Il-6 mRNA while upregulating Il-22. The partial restoration suggests that the gut microbiota contributes substantially to, but does not fully account for, the therapeutic effects of the formula.

Targeted metabolomics using LC-MS/MS with an isotope internal standard revealed that colitis reduced fecal levels of 5-hydroxyindole-3-acetic acid, indole-3-acetic acid, 3-hydroxy-DL-kynurenine, 3-indoleacetonitrile, nicotinic acid, kynurenic acid, and xanthurenic acid. The formula increased indole, indole-3-lactic acid, 5-hydroxyindole-3-acetic acid, 5-hydroxytryptophan, 3-hydroxy-DL-kynurenine, nicotinic acid, N-acetyl-serotonin, L-tryptophan, kynurenic acid, and serotonin, with significant differences in indole, indole-3-lactic acid, 3-hydroxy-DL-kynurenine, and serotonin. Spearman’s rank correlation analysis linked indole-3-lactic acid positively with Turicibacter and Romboutsia, and indole-3-acetic acid positively with Dubosiella, Monoglobus, Alistipes, Erysipelatoclostridium, and Faecalitalea, connecting specific microbial genera to specific metabolites.

The aryl hydrocarbon receptor normally remains dormant in the cytoplasm, bound in a complex with HSP90, XAP2, and p23. Upon ligand binding, the receptor translocates to the nucleus and initiates transcriptional regulation of downstream target genes such as CYP1A1, CYP1B1, and IL-22, maintaining intestinal homeostasis. In colitis mice, protein and mRNA levels of AhR, Cyp1a1, and Cyp1b1 decreased, while the formula significantly increased their expression. After antibiotic treatment, this effect was severely weakened, and fecal microbiota transplantation from formula-treated donors partially restored AhR expression in colon tissue, confirming the microbe-dependent mechanism.

In vitro experiments on HT-29 intestinal epithelial cells clarified the indirect nature of the activation. Within safe concentrations, the formula itself did not affect AhR protein expression or its target proteins CYP1A1 and CYP1B1. However, the tryptophan metabolite indole-3-lactic acid significantly promoted AhR expression. When the researchers modeled inflammation by stimulating HT-29 cells with 5 μg/mL lipoteichoic acid for 6 hours, treatment with 5 μM indole-3-lactic acid markedly reduced mRNA levels of IL-8, TNF-α, and IL-1β, and restored mRNA and protein levels of AhR, CYP1A1, and CYP1B1. The findings establish a microbiota-ILA-AhR axis as an important mechanism by which Baitouweng Tang alleviates colitis, providing a mechanistic foundation for clinical application and opening new avenues for microbiota-targeted or metabolite-based therapeutics for ulcerative colitis.

Subject of Research: Gut microbiota-dependent tryptophan metabolism and AhR signaling in the therapeutic effects of Baitouweng Tang on ulcerative colitis

Article Title: Gut Microbiota‐Dependent Tryptophan Metabolism Drives the Therapeutic Effects of Baitouweng Tang in Colitis via the AhR Pathway

Article References: Niu, C., Hua, Y., Kang, J., Li, F., Chen, B., Guo, R., & Wei, Y. (2026). Gut Microbiota‐Dependent Tryptophan Metabolism Drives the Therapeutic Effects of Baitouweng Tang in Colitis via the AhR Pathway. Food Science & Nutrition, 14(10), Article e72434. https://doi.org/10.1002/fsn3.72434

Image Credits: AI Generated

DOI: 10.1002/fsn3.72434

Keywords: Baitouweng Tang, ulcerative colitis, gut microbiota, tryptophan metabolism, indole-3-lactic acid, aryl hydrocarbon receptor, AhR pathway, traditional Chinese medicine, microbiota-targeted therapy, intestinal barrier, inflammatory bowel disease, DSS colitis model

Atopic dermatitis is far more than a cosmetic nuisance. It is a chronic, relapsing inflammatory skin disease characterized by eczematous lesions and intense itching, driven by a tangle of genetic predisposition, environmental triggers, skin barrier dysfunction, and immune dysregulation. While it affects roughly 7 to 10 percent of adults worldwide, prevalence in children can reach 25 percent, and Japanese surveys have reported rates as high as 27 percent among preschool children. The consequences ripple through entire households: disrupted sleep, impaired quality of life for children and their guardians, and the daily grind of applying multiple treatments. For most patients, topical therapies remain the mainstay of management, yet the workhorse drugs, topical corticosteroids, carry well-known limitations for long-term use, including the risk of skin atrophy.

Treatment guidelines in Japan emphasize reaching and maintaining a stable state in which signs and symptoms are absent or minimal without interfering with daily activities. Although biologics and other systemic therapies exist for refractory moderate-to-severe disease, the vast majority of children depend on creams and ointments. In recent years, nonsteroidal options such as Janus kinase inhibitors and phosphodiesterase-4 inhibitors have broadened the arsenal, but clinicians continue to call for effective topical agents with new mechanisms. Tapinarof answers that call with an unusual biological strategy: rather than suppressing inflammation broadly, it activates the aryl hydrocarbon receptor, a transcription factor that downregulates inflammatory cytokines implicated in atopic dermatitis while simultaneously upregulating components of the skin barrier.

That dual action is what makes the drug scientifically interesting. By engaging the aryl hydrocarbon receptor, tapinarof appears to improve measurable markers of barrier health, including stratum corneum hydration and transepidermal water loss, according to earlier clinical work in Japanese patients. The compound also activates the nuclear factor erythroid 2 related factor 2 pathway, which ramps up antioxidant enzymes and reduces oxidative stress in the skin. In effect, the drug does not merely quiet inflammation; it appears to help rebuild the defective barrier that lies at the heart of the disease. Tapinarof cream 1 percent is already approved for atopic dermatitis in patients aged 2 and older in the United States and the United Arab Emirates, and for patients 12 and older in Japan, where a phase 2 trial in younger children identified the 0.5 percent strength as the preferred formulation for this age group.

The new phase 3 trial, conducted between August 2023 and March 2025 at 27 sites in Japan, enrolled 162 children and was structured in two parts. The first was an 8-week, double-blind, vehicle-controlled period in which patients were randomized 2:1 to tapinarof cream 0.5 percent or an inactive vehicle cream, with allocation balanced by age category and baseline disease severity. The second was a 52-week open-label extension in which 151 patients who continued into that phase all received active treatment. Families applied a thin layer of cream once daily to all eczema lesions, excluding the hairy scalp, and children were required to have mild to severe disease at baseline, with an Eczema Area and Severity Index score of at least 5 and 5 to 30 percent of body surface area affected. The two groups were well matched, with mean baseline EASI scores of about 10.9 and 10.7 and roughly 60 percent of participants rated as having moderate disease.

The headline result was unambiguous. At week 8, 52.59 percent of children treated with tapinarof achieved a 75 percent or greater improvement in their EASI score, the trial’s primary endpoint, compared with just 12.60 percent of those on vehicle cream, a difference of 40 percentage points with a p value below 0.0001. On the key secondary endpoint, 26.2 percent of tapinarof-treated children reached treatment success on the Investigator’s Global Assessment, meaning their skin was rated clear or almost clear with at least a two-grade improvement, versus only 1.8 percent on vehicle. The mean percent reduction in EASI score was 68.28 percent with tapinarof compared with 23.01 percent with vehicle. Patient-reported measures reinforced the clinical picture: improvements in the Patient-Oriented Eczema Measure appeared from week 2 onward, and itch scores, recorded twice daily in diaries by guardians, fell rapidly after treatment began.

Perhaps the most striking findings emerged over the long haul. Among children who stayed on tapinarof, the EASI-75 response rate climbed from 53.4 percent at week 8 to 75.8 percent at week 32 and 80.2 percent at week 60, while global assessment treatment success rose from 24.3 percent to 48.5 percent and then 56.3 percent over the same span. Children who started on vehicle and switched to the active cream showed a rapid catch-up, reaching EASI-75 rates of 84.8 percent at week 32 and 82.8 percent at week 60. Notably, most patients continued applying the cream even after their lesions cleared, with roughly 80 percent accumulating at least 48 weeks of exposure, and the benefits were maintained without apparent differences between the 2-to-6 and 7-to-11 age groups. Rescue therapy with topical corticosteroids was needed by only about 20 percent of patients during the extension period.

The safety profile proved equally reassuring. Across the entire 60 weeks, no treatment-related serious adverse events were reported, and all treatment-related events were mild or moderate. During the double-blind period, adverse events occurred at similar rates in both groups, driven largely by everyday childhood infections such as nasopharyngitis and influenza. The most common treatment-related events with tapinarof were folliculitis and acne, including application-site folliculitis in 4.5 percent and acne in 3.9 percent of patients over the full trial. The authors attribute these follicular events to increased cornification within hair follicles, a downstream consequence of the drug’s upregulation of barrier proteins such as filaggrin, hornerin, and involucrin, giving them a morphology resembling keratosis pilaris. Only 2.6 percent of patients discontinued due to adverse events in the overall period, and pharmacokinetic sampling showed tapinarof plasma concentrations below the detection limit of 50 picograms per milliliter in at least 80 percent of children at every time point, confirming minimal systemic absorption.

The trial does have limitations worth noting. Most enrolled children had mild or moderate disease, and only four had severe eczema, so the findings may not fully generalize to the most severely affected patients. The comparator was vehicle cream rather than an active standard of care, leaving tapinarof’s superiority over existing topical therapies untested, and children under 2 years of age, in whom the disease is also prevalent, were not included, although a separate 52-week trial in patients aged 3 to 24 months is now underway in Japan. Long-term efficacy analyses also relied on observed cases without imputation and allowed treatment interruptions after clearance. Still, the overall message is clear: a once-daily, steroid-free cream that harnesses the aryl hydrocarbon receptor to both calm inflammation and rebuild the skin barrier delivered substantial, durable, and well-tolerated benefit in young children over more than a year of use. For families exhausted by the cycle of flares, steroids, and sleepless nights, tapinarof may soon offer a genuinely new way forward.

Subject of Research: Efficacy and safety of topical tapinarof cream in Japanese pediatric patients with atopic dermatitis

Article Title: Efficacy and safety of tapinarof cream once daily in Japanese pediatric patients with atopic dermatitis: a 60-week phase 3 trial consisting of an 8-week, double-blind, vehicle-controlled period and a 52-week, open-label extension period

Article References: Igarashi, A., Tsuji, G., Murata, R., Fukasawa, S., & Yamane, S. (2026). Efficacy and safety of tapinarof cream once daily in Japanese pediatric patients with atopic dermatitis: a 60-week phase 3 trial consisting of an 8-week, double-blind, vehicle-controlled period and a 52-week, open-label extension period. Journal of Cutaneous Immunology and Allergy, 9, Article 17307. https://doi.org/10.3389/jcia.2026.17307

Image Credits: AI Generated

DOI: 10.3389/jcia.2026.17307

Keywords: tapinarof, atopic dermatitis, aryl hydrocarbon receptor, pediatric patients, phase 3 trial, topical treatment, eczema, EASI-75, skin barrier, nonsteroidal therapy, folliculitis, Japan

The condition the researchers targeted is one of medicine’s quiet epidemics. Metabolic dysfunction-associated steatotic liver disease, or MASLD, affects the majority of people living with diabetes, and its incidence exceeds that of diabetic kidney disease. Because early-stage disease is usually symptom-free, it is frequently missed until fat overload, inflammation, and eventually fibrosis have taken hold. Left unchecked, it can progress to steatohepatitis and cirrhosis, sharply raising the risk of liver cancer, and it independently correlates with cardiovascular events and mortality. For a sugar that delivers roughly 70 percent of the sweetness of sucrose with minimal caloric contribution, the possibility of also easing this liver burden is a striking proposition.

To test the idea, a team at Jiangsu University worked with male C57BL/6J mice, feeding them a high-fat diet for four weeks and then injecting low doses of streptozotocin, a chemical that damages the insulin-producing beta cells of the pancreas. This combination reliably produces animals with high blood glucose, abnormal blood lipids, oxidative stress, and fat-laden livers, reproducing selected features of type 2 diabetes. One week after the final injection, mice with fasting blood glucose above 11.1 millimoles per liter were considered diabetic. The diabetic animals were then split into three groups of six: one left untreated, one given D-psicose at 2.5 percent of drinking water, and one given 5.0 percent. Treatment continued for twelve weeks alongside the high-fat diet.

The results were visible before any instrument was switched on. Livers from untreated diabetic mice were enlarged and pale, the classic gross appearance of severe lipid retention, while livers from the high-dose treatment group looked reddish and smooth, closely resembling those of healthy controls. Under the microscope the differences sharpened. Hematoxylin and eosin staining revealed that diabetic livers had lost their orderly cellular architecture, with hepatocytes ballooning and filling with vacuoles. Oil Red O staining, which highlights neutral triglycerides in bright red, confirmed massive fat deposits. D-psicose reversed these defects in a dose-dependent manner, preserving hepatic structure and clearing lipid droplets most effectively at the higher dose. Body weight, which had been falling steadily as the disease progressed, also stabilized in the treated animals.

Blood chemistry told the same story from a different angle. Untreated diabetic mice carried elevated total cholesterol, triglycerides, and LDL cholesterol, along with depressed HDL, the protective fraction. They also showed raised alanine and aspartate aminotransferases, the enzymes that leak into the bloodstream when liver cells are injured, and heightened circulating levels of the inflammatory cytokines TNF-alpha, IL-6, and IL-1beta. Twelve weeks of D-psicose shifted all of these indices back toward the healthy profile, with the high-dose regimen again producing the larger effect. The pattern suggests the sugar was not merely masking symptoms but correcting an underlying imbalance in how the diabetic liver handles fat and inflammation.

The molecular explanation begins with lipid metabolism genes. In diabetic livers, the transcription factors and enzymes that drive de novo fat synthesis, SREBP-1c and FASN, were significantly upregulated, while PPAR-alpha, the master regulator of fatty acid beta-oxidation, was suppressed. D-psicose flipped this program: SREBP-1c and FASN fell in a dose-dependent fashion and PPAR-alpha recovered toward normal levels. The authors describe this as a dual mechanism of increasing expenditure and reducing intake, simultaneously blocking new fat production and burning existing fat. The treatment also restored the transcription of antioxidant enzymes SOD1 and GPX1, which diabetes had suppressed, and pushed down Col1a1 and TGF-beta1, two markers of the pro-fibrotic signaling that threatens to scar the liver permanently.

The most novel part of the study concerns the gut-liver axis. Sequencing the V3-V4 region of the bacterial 16S rRNA gene from colonic contents showed that diabetes had skewed the microbial community, inflating the Firmicutes-to-Bacteroidota ratio and expanding Proteobacteria, a phylum often associated with inflammation. At the genus level, diabetic mice had depleted Akkermansia, Lactobacillus, and several other taxa, while Alistipes, Parabacteroides, and Anaerotruncus expanded. D-psicose treatment recalibrated these imbalances, pulling the community profile back toward that of healthy controls. In parallel, the sugar repaired the intestinal wall itself: villi that had become stunted and disorganized regained their height, the tight-junction proteins ZO-1 and Occludin, which seal the gaps between epithelial cells, recovered their continuous staining pattern, and serum lipopolysaccharide, a marker of bacterial endotoxin leaking through a leaky gut, dropped significantly.

Those microbial and barrier changes coincided with a measurable shift in tryptophan chemistry. Using targeted UPLC-MS/MS, the researchers found that diabetic mice had depleted serum tryptophan, elevated kynurenine, and a raised kynurenine-to-tryptophan ratio, a signature of overactive IDO/TDO catabolism, together with reduced levels of indole-3-propionic acid, a microbially derived metabolite with known anti-inflammatory properties. D-psicose reversed every one of these abnormalities. In the liver, the enzyme TDO2, the rate-limiting step of the tryptophan-kynurenine pathway, had been overexpressed in diabetes while the aryl hydrocarbon receptor, or AhR, a nuclear sensor for microbial indole metabolites, had been suppressed. Treatment lowered TDO2 and restored AhR at both the mRNA and protein levels. At the same time, the phosphorylation ratio of NF-kappaB p65, the activated form of the central inflammatory transcription factor, fell from its diabetic high back toward normal.

Untargeted serum metabolomics reinforced the picture. Principal component analysis separated the three groups in both ionization modes, and internally validated OPLS-DA models, checked with seven-fold cross-validation and 200-permutation testing, confirmed that D-psicose shifted the metabolic profile toward that of healthy animals. KEGG enrichment pointed to pathways including tryptophan metabolism, arachidonic acid metabolism, biotin metabolism, and steroid hormone biosynthesis as candidate biological contexts for the changes. The authors are careful, however, about what these data can and cannot prove. Because 16S sequencing is taxonomic rather than functional, the study cannot show that Akkermansia or Lactobacillus actually produced the altered metabolites, and because AhR activity was never directly perturbed, the gut microbiota-tryptophan-AhR chain remains a coherent hypothesis rather than a demonstrated causal mechanism.

The limitations are acknowledged candidly. The HFD/STZ model does not capture the full heterogeneity or natural history of human diabetic liver disease, the sample size was modest at six animals per group, and fasting glucose was used only to confirm diabetes induction, with no assessment of glucose tolerance, insulin sensitivity, or glycated hemoglobin. No fecal microbiota transplantation, germ-free experiments, or pharmacological AhR ligands were deployed to test causality. Still, the convergence of evidence is notable: a widely available rare sugar improved liver histology, blood lipids, inflammatory cytokines, antioxidant defenses, and fibrosis markers in diabetic mice, all while reshaping the gut ecosystem, restoring barrier integrity, and rebalancing a microbial-metabolic signaling axis increasingly implicated in metabolic disease. If future studies in complementary models and, ultimately, human trials confirm these coordinated effects, D-allulose could evolve from a niche sweetener into a genuine dietary tool against one of diabetes’ most overlooked complications.

Subject of Research: Effects of D-psicose (D-allulose) on hepatic steatosis, gut microbiota, and tryptophan-AhR signaling in a mouse model of type 2 diabetes

Article Title: D‐Psicose Attenuates Hepatic Steatosis and Inflammatory Injury in HFD/STZ‐Induced T2DM Mice and Is Associated With Alterations in Gut Microbiota, Tryptophan Metabolism, and Hepatic AhR‐Related Signaling

Article References: Wu, L., Dong, X., Sun, W., Xu, H., Xie, Y., Liu, X., Liu, X., Ali, A., & Shao, K. (2026). D‐Psicose Attenuates Hepatic Steatosis and Inflammatory Injury in HFD / STZ ‐Induced T2DM Mice and Is Associated With Alterations in Gut Microbiota, Tryptophan Metabolism, and Hepatic AhR ‐Related Signaling. Food Science & Nutrition, 14(10), Article e72455. https://doi.org/10.1002/fsn3.72455

Image Credits: AI Generated

DOI: 10.1002/fsn3.72455

Keywords: D-allulose, D-psicose, type 2 diabetes, fatty liver, MASLD, gut microbiota, tryptophan metabolism, aryl hydrocarbon receptor, NF-kappaB, intestinal barrier, Akkermansia, metabolomics

The research team, led by scientists at Kunming University of Science and Technology in China, started with a simple culinary insight. Tamarind pulp is naturally packed with dietary fiber, polysaccharides, polyphenols such as quercetin and proanthocyanidins, and organic acids, all of which have documented digestive benefits. Fermentation, the researchers reasoned, could amplify these properties by breaking down complex molecules into more bioavailable forms and by seeding the gut with beneficial organisms. They inoculated sterilized tamarind pulp with a five-strain cocktail, including Kluyveromyces marxianus, two Lactobacillus paracasei strains, and two Pediococcus pentosaceus strains, and let it ferment anaerobically for 48 hours before heat-treating the mixture at 60 degrees Celsius to halt microbial activity while preserving the metabolites the microbes had produced.

To test the preparation, the team induced constipation in mice with loperamide, a drug that slows intestinal transit by acting on opioid receptors. The animals were divided into groups receiving saline, the laxative bisacodyl as a positive control, unfermented tamarind pulp, or the fermented product at either high or low dose. Over the course of the experiment, the differences became dramatic. Mice given the high-dose fermented pulp saw their small intestine transit rate jump by 57.2 percent compared with untreated constipated animals, restoring transit to levels statistically indistinguishable from healthy controls. Fecal moisture content rose by 65.9 percent, pellet output nearly tripled, and colon length, which had shrunk by nearly 15 percent under loperamide, largely recovered.

Perhaps most tellingly, the fermented product outperformed both the unfermented pulp and, in several measures, the commercial laxative itself. High-dose fermented tamarind produced fecal hydration exceeding that of the bisacodyl group and raised levels of the excitatory neurotransmitters motilin and substance P by 58 and 68 percent respectively, while suppressing the inhibitory peptide VIP. Histological examination of colon tissue confirmed the physiological gains: fermented pulp preserved villus architecture, maintained epithelial integrity, and sharply reduced inflammatory cell infiltration, with histological scores falling to near-control levels.

Digging into the mechanism, the researchers turned to multi-omics profiling. Sixteen S ribosomal RNA sequencing revealed that constipation had slashed microbial diversity and skewed the community toward a high Bacillota-to-Bacteroidota ratio, a signature of dysbiosis. Fermented tamarind reversed these changes, enriching short-chain fatty acid producers such as Muribaculaceae, Prevotellaceae, and Rikenellaceae, while suppressing Desulfovibrio, a sulfate-reducing bacterium that generates hydrogen sulfide toxic to the intestinal epithelium. The functional predictions mirrored these shifts: enzymes that hydrolyze dietary fiber into fermentable sugars rebounded, and pathways for propionate and butyrate biosynthesis were upregulated.

The metabolic payoff was measurable. Total fecal short-chain fatty acids, which had collapsed by nearly half in constipated mice, more than doubled after high-dose fermented pulp treatment, rising 107 percent, with acetic acid, isobutyric acid, and isovaleric acid all climbing significantly. These fatty acids do double duty: they stimulate peristalsis through G-protein-coupled receptors and serotonin release, and they calm inflammation. Consistent with this, the fermented treatment dose-dependently reduced colonic levels of the inflammatory cytokines IL-6, IL-1β, and TNF-α, with the high dose cutting IL-6 by 60 percent and TNF-α by 45 percent.

The deepest mechanistic insight, however, came from the metabolomics data. Fermentation dramatically reshaped tryptophan metabolism, a central hub connecting gut microbes to host immunity and neural signaling. High-dose fermented pulp significantly increased indole-3-propionic acid, indole-3-acetic acid, and indole-3-pyruvic acid, microbial indole derivatives known to activate the aryl hydrocarbon receptor, or AhR, a ligand-activated transcription factor that maintains intestinal immune balance. It also boosted serotonergic intermediates including 5-hydroxytryptophan, the direct precursor of serotonin, which drives peristalsis and fluid secretion through enteric neurons, while reducing kynurenic acid, a marker of the alternative kynurenine pathway. Immunohistochemistry confirmed that the fermented product restored colonic expression of tryptophan hydroxylase 1, serotonin, and the serotonin 4 receptor, the molecular machinery of gut motility.

These metabolic shifts converged on a specific signaling axis. Loperamide had suppressed AhR expression and activated the NLRP3 inflammasome, an innate immune complex that matures the pro-inflammatory cytokines IL-1β and IL-18. High-dose fermented tamarind reversed both changes, roughly doubling AhR expression and halving NLRP3 levels. Fermentation also appeared to biotransform the pulp’s abundant quercetin into smaller phenolic acids, including 3-hydroxyphenylacetic acid and 3,4-dihydroxyphenylacetic acid, compounds with antioxidant and anti-inflammatory properties that correlated with improved motility and reduced cytokines.

To establish causality rather than mere correlation, the team ran a second experiment using CH-223191, a specific AhR antagonist, and MCC950, an NLRP3 inhibitor. When constipated mice received fermented tamarind alongside the AhR blocker, the therapeutic benefits largely evaporated: defecation frequency, transit rate, and fecal hydration all fell back toward model-group levels, and the increases in the anti-inflammatory cytokine IL-22 and the AhR target gene CYP1A1 were abolished. This pharmacological validation strongly supports the conclusion that the anti-constipation effect depends on AhR signaling and its downstream suppression of inflammasome-mediated inflammation.

The authors are careful to note the limitations. The work was conducted in a loperamide-induced mouse model, which mimics slow-transit constipation but does not capture the full heterogeneity of human disease, and the contributions of individual metabolites such as indole-3-propionic acid remain correlative pending targeted validation. Metagenomic and transcriptomic studies will be needed to fully map the microbial genes and host transcriptional programs involved. Still, the study positions heat-inactivated fermented tamarind pulp as a promising postbiotic candidate, one that works not by simply lubricating the bowel but by re-engineering the gut’s microbial ecology, metabolic chemistry, and immune signaling simultaneously. For a condition affecting hundreds of millions of people, a spoonful of fermented fruit pulp, backed by a clearly defined molecular mechanism, is an appealing prospect, and one that human trials will now be eager to test.

Subject of Research: Probiotic-fermented tamarind pulp as a postbiotic therapy for constipation via gut microbiota, tryptophan metabolism, and AhR–NLRP3 signaling

Article Title: Heat-inactivated probiotic-fermented tamarind pulp alleviates constipation by modulating gut tryptophan catabolism and the AhR NLRP3 axis

Article References: Gui, X., Yuan, C., Huang, S., Huang, K., Wu, L., Song, Z., Wang, T., Liu, Z., Liu, X., Mu, M., Yi, J., & Chu, C. (2026). Heat-inactivated probiotic-fermented tamarind pulp alleviates constipation by modulating gut tryptophan catabolism and the AhR NLRP3 axis. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.10.014

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.10.014

Keywords: constipation, tamarind, probiotics, postbiotics, gut microbiota, short-chain fatty acids, tryptophan metabolism, aryl hydrocarbon receptor, NLRP3 inflammasome, fermented foods, intestinal motility, serotonin

That gap has now been substantially closed. A team of researchers led by Marco Jost of Harvard Medical School, working alongside colleagues including Seth Rakoff-Nahoum, Emily Balskus of Harvard University and the Howard Hughes Medical Institute, and Michael Fischbach of Stanford University, has deployed genome-scale CRISPR screening to systematically identify the regulators of AHR signaling in a human hepatocyte model. The study, published in Genome Biology, represents one of the most comprehensive efforts to date to chart the wiring diagram of this enigmatic receptor. Rather than examining candidate genes one at a time, the team perturbed virtually every gene in the human genome and measured the consequences for AHR activity, allowing the data to reveal the regulatory architecture on an unbiased, genome-wide scale.

The technical approach at the heart of the study is CRISPR interference, or CRISPRi, a refined application of the gene-editing technology that does not cut DNA. Instead, a catalytically dead form of the Cas9 protein is guided to specific genes, where it acts as a reversible brake on transcription, silencing expression without altering the underlying genetic code. By delivering a genome-wide library of guide RNAs into cells engineered so that AHR activation produces a measurable fluorescent or luminescent readout, the researchers could simultaneously test the effect of losing each of roughly twenty thousand human genes on the signaling pathway. Genes whose silencing boosted the readout are candidate negative regulators of AHR; those whose silencing dampened the signal are candidate positive regulators. The beauty of the method lies in its parallelism: thousands of regulatory hypotheses are tested in a single experiment, and the strength of each guide RNA’s enrichment or depletion across the population quantifies the effect.

The results provided immediate validation that the screens had captured genuine biology. Among the hits recovered were the core components of the canonical AHR pathway itself, including the receptor, its nuclear translocator partner ARNT, and factors involved in ligand binding and receptor degradation. This internal consistency mattered, because a screen that failed to rediscover the known players could not be trusted to reveal unknown ones. But beyond the expected genes, the datasets surfaced a large and previously unmapped network of regulators, many of which had never been connected to AHR biology. The breadth of the hit list carried its own message: AHR signaling is not an isolated detoxification circuit but a process deeply interwoven with the general machinery of human cells, touching protein synthesis, trafficking, degradation, and chromatin regulation.

One of the study’s most striking findings concerns the fate of the receptor protein itself. The team identified the E3 ubiquitin ligase UBR5 as a factor that sustains AHR signaling by counteracting the degradation of ligand-bound AHR. Ubiquitin ligases are the enzymes that tag proteins with ubiquitin marks, often condemning them to destruction by the proteasome, and the interplay between AHR and the ubiquitin-proteasome system has long been known to shape receptor levels. What the new work adds is a specific, experimentally validated node within that system: when UBR5 function was compromised, ligand-activated AHR was degraded more readily, and the downstream transcriptional program weakened. In other words, UBR5 acts as a guardian of the activated receptor, extending the window during which AHR can drive gene expression after it encounters its chemical triggers.

The screens also probed how regulation depends on context, a question of particular importance for a receptor that responds to chemically diverse ligands ranging from environmental toxins to microbially derived metabolites such as urolithins, the gut bacterial products that the team included in their chemical analyses. By repeating CRISPRi screens with different inducing molecules, the researchers could classify regulators into those that act generally across all ligands and those whose effects are specific to particular inducers. This distinction is more than a technical curiosity. General regulators represent the pathway’s universal infrastructure, while ligand-specific and cell-type-specific regulators offer potential points of selective manipulation. A drug aimed at a general node would shift AHR activity everywhere; one aimed at a context-specific node could, in principle, tune the receptor’s response to microbial metabolites in the gut without disturbing its detoxification duties in the liver.

That therapeutic logic runs throughout the study’s conclusions. Because AHR sits at the interface of environment, diet, microbiome, and immunity, pharmaceutical interest in the receptor has grown steadily, with attempts to modulate it for inflammatory bowel disease, autoimmune conditions, and metabolic disorders. The obstacle has always been specificity: blunt activation or inhibition of AHR produces widespread effects, some beneficial and some harmful. By identifying cell-type-specific and ligand-specific regulatory components, the new map provides a catalog of candidate targets for more surgical interventions. The authors frame these context-dependent nodes as potential handles for manipulating AHR signaling in a targeted manner for therapeutic benefit, a framing that turns a basic-science dataset into a starting point for drug discovery.

The study also carries implications for understanding host-microbe interactions, one of the most active frontiers in biology. Gut bacteria generate a pharmacopeia of small molecules, and AHR is one of the principal receptors through which these metabolites communicate with the host immune system. Microbial ligands of AHR have been implicated in maintaining the intestinal barrier, calibrating immune responses, and protecting against colitis. A complete regulatory map of the pathway in human cells gives researchers a systematic way to ask how host genetics shapes sensitivity to microbial chemistry, and why individuals or disease states might differ in their responses to the same bacterial metabolites. The integration of chemical screening with genetic screening in this work, including the use of a urolithin library prepared specifically for the study, exemplifies the kind of combined approach that the field of host-microbe chemical biology increasingly demands.

Methodologically, the work demonstrates how far functional genomics has come in dissecting signaling pathways that were once studied gene by gene over decades. The researchers supplemented their primary genome-wide screens with focused sublibrary screens, individual validation assays using independently designed guide RNAs, transcriptional measurements, and biochemical analyses of receptor protein turnover, including western blot experiments documented with full-length unprocessed scans. The classification of hits by activation phenotype across multiple inducers, and the assessment of regulator activity across different cell types, turned a flat list of genes into a structured network with layers of general, ligand-specific, and cell-type-specific control. The datasets, released openly with the article, include raw and analyzed screen data, guide RNA sequences, and primer sequences, providing a resource that other laboratories can mine and reanalyze.

What emerges from the study is a picture of AHR as a receptor embedded in a dense web of cellular governance, its activity shaped not only by which ligand is present but by an extensive cast of proteins controlling its expression, abundance, localization, and longevity. The identification of UBR5 as a protector of the activated receptor offers a mechanistic vignette of how that governance works at the level of protein stability, while the broader network suggests that perturbations far removed from the canonical pathway could nonetheless modulate how human cells respond to the chemical world. For a receptor whose dysfunction has been tied to metabolic and inflammatory disease, and whose normal function depends on a constant dialogue between the body and its microbial inhabitants, the new regulatory map is both a reference atlas and a hypothesis engine. It transforms AHR from a well-studied but incompletely understood sensor into a system whose vulnerabilities and control points can, for the first time, be surveyed in their entirety.

Subject of Research: Genome-scale CRISPR identification of regulators of aryl hydrocarbon receptor signaling in human cells

Article Title: Identification of regulators of aryl hydrocarbon receptor signaling in human cells by genome-scale CRISPR screening

Article References: Verma, M., Adamthwaite, M. L., Desai, K., Ding, Y., Wang, X., Bae, M., Rakoff-Nahoum, S., Balskus, E. P., Fischbach, M. A., & Jost, M. (2026). Identification of regulators of aryl hydrocarbon receptor signaling in human cells by genome-scale CRISPR screening. Genome Biology. https://doi.org/10.1186/s13059-026-04299-1

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04299-1

Keywords: aryl hydrocarbon receptor, CRISPR screening, gene regulation, transcription factor, UBR5, E3 ubiquitin ligase, gut microbiome, microbial metabolites, xenobiotic detoxification, host-microbe interactions, inflammatory disease, hepatocytes

Necrotizing enterocolitis, or NEC, is a devastating inflammatory bowel condition that strikes predominantly premature and very low birth weight infants. In NEC, the fragile lining of the intestine becomes inflamed, breaks down, and in severe cases the bowel tissue dies, forcing emergency surgery and, too often, ending in death. Treatment options remain limited: clinicians can support the infant with antibiotics, bowel rest, and surgery, but there is no therapy that reliably halts the disease once it takes hold. That gap has pushed researchers toward prevention, and the gut microbiome has emerged as the most promising frontier. Decades of observational work have shown that infants who go on to develop NEC often carry a disrupted community of intestinal bacteria, dominated by potentially harmful species and lacking the beneficial microbes that normally colonize a healthy newborn gut.

Bifidobacteria are among the earliest and most important colonizers of the healthy infant intestine, thriving on the complex sugars found in human milk and helping to train the newborn immune system. Probiotic supplementation with Bifidobacterium strains has been associated in clinical trials and systematic reviews with reduced mortality and lower rates of NEC in preterm infants, yet the molecular machinery behind this protection has remained frustratingly opaque. The new study set out to close that gap by tracing the entire chain of events, from shifts in microbial communities to changes in host metabolism and gene expression, in a controlled animal model of the disease.

The researchers divided neonatal rats into three groups: a healthy control group, a group subjected to an established NEC protocol combining formula feeding and hypoxic stress, and a group given the NEC protocol along with daily supplementation of Bifidobacterium BB-12. The results were striking. Treated animals showed markedly milder clinical symptoms, less severe intestinal tissue damage under the microscope, and significantly improved survival compared with untreated NEC animals. Blood tests revealed that the probiotic suppressed the surge of inflammatory cytokines, the chemical alarm signals that normally flood the circulation during the disease, suggesting that the benefit extended beyond the bowel wall to the whole body’s inflammatory state.

To understand what was happening inside the gut, the team performed 16S rRNA gene sequencing, a technique that catalogs the bacterial species present in a sample by reading a conserved genetic marker. In the untreated NEC animals, the microbial community was skewed toward Proteobacteria, a phylum that includes many opportunistic pathogens, with a notable expansion of Shigella and Escherichia species. In the probiotic-treated animals, that balance shifted back toward health: beneficial groups including Bacteroidetes, Actinobacteria, and Bifidobacterium itself increased, while the pathogenic Proteobacteria receded. The treated rats also recovered greater overall microbial diversity, a hallmark of a resilient gut ecosystem that had been stripped away by the disease process.

The pivotal discovery, however, lay in a signaling pathway that connects bacterial chemistry to host gene expression. The aryl hydrocarbon receptor, or AhR, is a molecular sensor found inside cells throughout the body, best known for its role in detoxifying environmental compounds but increasingly recognized as a critical regulator of intestinal immunity. When ligands bind AhR, it travels to the nucleus and switches on target genes, including CYP1A1, a canonical readout of pathway activity. Previous work has shown that activating AhR in the gut protects against experimental NEC, and that microbial metabolites derived from the amino acid tryptophan are among the most potent natural activators of this receptor. The new study found that Bifidobacterium-treated NEC rats had significantly upregulated AhR and CYP1A1 expression in the intestine, and that the degree of pathway activation correlated negatively with the severity of tissue damage, hinting that the pathway was actively protecting the bowel.

Where were the ligands coming from? Colon metabolomics, an unbiased chemical survey of the gut contents, provided the answer. The probiotic-treated animals showed elevated levels of several indole derivatives, compounds produced when bacteria metabolize dietary tryptophan. Among them was indole-3-lactic acid, or ILA, a metabolite that Bifidobacterium species are particularly adept at generating and that has previously been shown to exert anti-inflammatory effects on the immature intestine. Also enriched were indole-3-aldehyde and 3-hydroxyanthranilic acid, both of which have been implicated in AhR signaling and gut barrier maintenance in earlier studies of inflammatory bowel disease and NEC.

To test whether ILA was truly responsible for the anti-inflammatory effect, the researchers moved to a controlled in vitro system. They exposed intestinal epithelial cells to lipopolysaccharide, a component of bacterial outer membranes that reliably triggers a strong inflammatory response, mimicking the bacterial assault that contributes to NEC. When ILA was added, the cells responded by ramping up AhR and CYP1A1 expression and by producing fewer inflammatory mediators. The decisive experiment came next: when the researchers knocked down AhR expression in the cells using molecular tools, the protective effect of ILA largely disappeared. That loss-of-function result is the strongest evidence in the study that the metabolite works through the receptor rather than some parallel route, anchoring the entire mechanistic story.

Taken together, the findings sketch a coherent model of probiotic action. Bifidobacterium BB-12, once established in the gut, reshapes the microbial community in ways that favor beneficial species and displace pathogens. It simultaneously boosts the production of tryptophan-derived indole metabolites, particularly ILA, which activate the AhR-CYP1A1 axis in the intestinal lining. That activation suppresses inflammatory signaling, preserves the epithelial barrier, and reduces tissue injury, which in turn improves survival. The study’s authors suggest that this framework points toward new intervention strategies, whether through carefully selected microbial metabolites delivered directly or through pharmacological AhR agonists designed to mimic the probiotic’s effect without introducing live bacteria.

Important caveats remain before these results can shape clinical practice. The work was conducted in a rat model, and while animal models of NEC have historically predicted human biology reasonably well, neonatal physiology, microbial colonization patterns, and immune development differ between species. Clinical questions also persist around probiotic safety in the most vulnerable infants; regulatory agencies have issued safety communications about the risk of invasive infection from live probiotic preparations in preterm babies, which is precisely why metabolite-based or receptor-targeted therapies are attractive alternatives. Still, by connecting a familiar probiotic, a measurable metabolic product, and a well-characterized immune receptor into a single causal chain, the study gives researchers a concrete set of targets to pursue and brings the field a step closer to interventions that could protect the smallest patients from one of neonatology’s most dangerous diseases.

Subject of Research: Probiotic modulation of gut microbiota and aryl hydrocarbon receptor signaling in a neonatal rat model of necrotizing enterocolitis

Article Title: Bifidobacterium modulates gut microbiota and aryl hydrocarbon receptor signaling in necrotizing enterocolitis rat model

Article References: Liu, W., Liu, Z., Yang, H., Fu, C., Wang, H., Chen, D., & Xu, J. (2026). Bifidobacterium modulates gut microbiota and aryl hydrocarbon receptor signaling in necrotizing enterocolitis rat model. Pediatric Research. https://doi.org/10.1038/s41390-026-05388-4

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05388-4

Keywords: necrotizing enterocolitis, Bifidobacterium, probiotics, gut microbiota, aryl hydrocarbon receptor, indole-3-lactic acid, tryptophan metabolites, CYP1A1, neonatal rats, intestinal inflammation, preterm infants, metabolomics

The review builds on the concept of the microbiota-gut-brain axis, a bidirectional communication network linking the gastrointestinal tract with the central nervous system through neural, endocrine, immune, and metabolic pathways. Gut-derived signals can reach the brain via vagal afferents, circulating immune mediators, microbial metabolites, and gut hormones, while autonomic and hypothalamic-pituitary-adrenal signaling can in turn modify intestinal motility, barrier function, and microbial composition. Microbial products such as short-chain fatty acids, tryptophan derivatives, and lipopolysaccharide are known to influence blood-brain barrier homeostasis, microglial activity, immune-cell differentiation, and epigenetic regulation. Much of this mechanistic evidence, however, comes from germ-free animals and non-cancerous neurological models, and its direct relevance to human glioblastoma remains incompletely established.

The tumor microenvironment of glioblastoma provides a plausible target for such systemic signals. The tumor is dominated by myeloid cells, particularly tumor-associated macrophages that arise from both resident microglia and infiltrating monocytes. Single-cell studies show these populations occupy distinct spatial niches and transcriptional states, rendering the conventional M1/M2 classification overly simplistic. Glioma cells recruit and shape myeloid cells through mediators including colony-stimulating factor 1, CCL2, transforming growth factor-beta, and interleukin-10, while regulatory T cells and exhausted T cells expressing PD-1, TIM-3, LAG-3, and CTLA-4 further entrench immune suppression. Immune dysfunction also extends beyond the tumor itself: treatment-naive patients show sequestration of naive T cells in the bone marrow, impairing T-cell egress and helping explain why checkpoint blockade alone has failed in this disease.

Against this backdrop, experimental evidence from mouse models has begun to suggest that gut microbes can indeed modulate glioma-associated immunity. In one of the earliest glioma-specific studies, chronic antibiotic exposure in mice bearing intracranial GL261 tumors altered intestinal bacterial composition, reduced cytotoxic natural-killer-cell subsets, modified microglial inflammatory proteins, and was accompanied by accelerated tumor growth. A subsequent orthotopic model showed that antibiotic-induced dysbiosis reduced short-chain fatty acid concentrations in blood and tumor tissue and sped tumor progression, while oral supplementation with these metabolites increased glycolytic activity in tumor-associated macrophages and improved outcomes. More strikingly, fecal microbiota transfer experiments demonstrated that mice receiving microbiota from patients with high-grade glioma developed faster-growing tumors than mice receiving microbiota from healthy donors, with bacterial genera such as Eisenbergiella and Merdimonas enriched in the recipients.

Metabolite signaling sits at the heart of these mechanisms, but the review stresses a critical caveat: a metabolite relevant to glioblastoma is not necessarily microbiota-derived. Short-chain fatty acids such as butyrate act through G-protein-coupled receptors and epigenetic mechanisms, inhibiting histone deacetylases and influencing regulatory T-cell differentiation. Sodium butyrate has reduced proliferation and promoted apoptosis in human glioma cell lines, and in one mouse study it increased PD-L1 expression and enhanced the efficacy of anti-PD-1 therapy. Yet the millimolar concentrations used in vitro do not demonstrate that microbiota-derived butyrate reaches human glioblastoma tissue at comparable levels. Similarly, the kynurenine pathway engages the aryl hydrocarbon receptor, but in glioblastoma the strongest evidence points to kynurenine produced by tumor cells themselves rather than by gut microbes. A recent study also showed that tumor-cell-derived spermidine suppressed CD8-positive T-cell activity and that blocking its synthesis prolonged survival in mice, again without any established microbial contribution.

Perhaps the most provocative findings concern microbial material detected within human brain tumors themselves. A prospective multi-institutional study of 243 samples from 221 patients combined RNA-based fluorescence in situ hybridization, immunohistochemistry, spatial imaging, sequencing, and culturomics, detecting bacterial 16S rRNA and lipopolysaccharide signals in subsets of glioma and metastatic samples, including within tumor, immune, and stromal cells. Signals assigned to genera including Fusobacterium, Prevotella, and Veillonella partially overlapped with matched oral or gut communities. Separately, an immunopeptidomic analysis of tumors from nineteen patients identified 344 distinct bacteria-associated peptides bound to HLA class II molecules, and some of these peptides were recognized by tumor-infiltrating T cells, including a CD4-positive T-cell clone that cross-recognized both a mutated glioblastoma antigen and several microbial peptides.

These discoveries come with heavy methodological caveats. Brain tumors contain extremely low microbial biomass, making sequencing studies vulnerable to reagent contamination, environmental DNA, and computational misclassification. The 2024 retraction of a prominent TCGA-based cancer microbial-signature study underscored the danger. Standard culture failed to recover a readily cultivable bacterial community from the prospective brain-tumor samples, the signals were sparse and heterogeneous, and no association with clinical outcome was established. The review therefore recommends reserving the terms microbiota and microbiome for settings where a diverse, biologically active community is supported by adequate evidence, and instead using phrases like microbial signals or bacterial elements until viability, replication, and function are demonstrated. Rigorous negative controls, orthogonal spatial validation, and viability assessment are deemed essential before any claim of stable intratumoral colonization can stand.

On the translational front, the review finds everything still at the earliest stage. No gut- or tumor-derived microbial biomarker has been independently validated for glioblastoma diagnosis, prognosis, or treatment selection, and current prospective studies such as THERABIOME-GBM remain observational. Fecal microbiota transplantation has shown clinical proof of principle in melanoma, where it can promote responses to checkpoint inhibitors, but no therapeutic trial exists in glioblastoma, and safety concerns are serious: FMT has transmitted multidrug-resistant organisms to immunocompromised recipients, including a fatal infection. Probiotic combinations of Bifidobacterium lactis and Lactobacillus plantarum reduced tumor volume in mice, and even dietary manipulations such as a short-term high-glucose drink or aspartame exposure altered tumor biology in animal models, but the authors explicitly caution that none of these findings justifies recommending any microbiome-directed intervention to patients.

Looking ahead, the review identifies several promising but speculative directions. One is the intersection between microbiota-associated inflammation and the circadian-glymphatic-melatonergic network, where experimental sleep-restriction data suggest melatonin can preserve glymphatic function, and a proposed but unproven pathway links aryl hydrocarbon receptor activity to melatonin metabolism and N-acetylserotonin signaling through the TrkB receptor. Another is bacteriophage-based modulation, which in colorectal cancer models has successfully targeted Fusobacterium nucleatum to augment chemotherapy, though no viable bacterial driver has been validated in glioblastoma and delivery across the blood-brain barrier remains unsolved. The authors conclude that progress will depend on source attribution, orthogonal validation, perturbation-and-rescue experiments, longitudinal human sampling, and replication across centers. The key distinction, they argue, is between a microbiota-associated signal and a clinically established mechanism, and only evidence that a defined microbial feature is reproducible, mechanistically linked to tumor or immune phenotypes, and safely modifiable will allow microbiota research to contribute meaningfully to precision neuro-oncology.

Subject of Research: The role of the gut microbiome and microbial metabolites in glioblastoma tumor-immune interactions and translational oncology

Article Title: The Microbiome in Glioblastoma: Mechanisms, Tumor–Immune Interactions, and Translational Perspectives

Article References: AlRamadneh, T. N., Jyothi‐S, R., Priyadarshini‐Nayak, P., Nanda, A., Al‐Hasnaawei, S., Bhatt, A., Singh‐Chauhan, A., Singla, S., & Mishra, M. K. (2026). The Microbiome in Glioblastoma: Mechanisms, Tumor–Immune Interactions, and Translational Perspectives. MicrobiologyOpen, 15(5), Article e70431. https://doi.org/10.1002/mbo3.70431

Image Credits: AI Generated

DOI: 10.1002/mbo3.70431

Keywords: glioblastoma, gut microbiome, microbiota-gut-brain axis, tumor microenvironment, short-chain fatty acids, kynurenine, aryl hydrocarbon receptor, tumor-associated macrophages, immune checkpoint inhibitors, fecal microbiota transplantation, intratumoral bacteria, HLA peptides

The team, led by Dr. Corinne Benakis, set out to understand how signals originating in the intestine reach the immune cells that help determine stroke outcome. Their starting point was an observation in mouse models of severe stroke: bacteria capable of producing a metabolite called indole became more abundant in the gut following the injury. Indole is a small molecule with a distinctive property that makes it a plausible messenger between microbes and the body — it is produced only in the gut, by bacteria that carry a gene known as tnaA. That gene encodes an enzyme allowing these microbes to convert tryptophan, an amino acid obtained from food, into indole. In other words, a dietary building block is transformed by bacterial metabolism into a signaling molecule that can act on the host immune system.

When the researchers examined what this meant for the brain, the results were striking. In mice, the presence of indole-producing bacteria worsened brain injury after stroke. This established a causal link rather than a mere correlation: the microbial metabolite was not simply a byproduct of the disease state but an active participant in shaping how much damage the stroke inflicted. The discovery adds stroke to a growing list of conditions in which gut-derived molecules have been shown to reach beyond the digestive tract and influence distant organs, often through the immune system.

The next question was mechanistic: how does a molecule made in the gut alter events in the brain? The answer lies with a receptor called the aryl hydrocarbon receptor, or AHR, a sensor found in dendritic cells. Dendritic cells are immune sentinels that patrol the intestinal lining, sampling their surroundings and helping to coordinate immune responses throughout the body. Indole, the team found, acts on AHR in these cells, and that interaction changes their behavior in ways that matter for stroke recovery.

To test this directly, the researchers switched off AHR specifically in dendritic cells. The effect on the mice was protective: without the receptor, they were better shielded against brain injury after stroke. The reason, according to the study, lies in how the cells behave once the indole signal is removed. Dr. Rosa Delgado Jiménez, who shares first authorship of the paper with Alexandria Ruggles and Mujeeb Adedokun, described the change in vivid terms. Dendritic cells, she explained, have long extensions, like arms, that allow them to sense changes in their environment, including metabolites produced by gut bacteria. When AHR was switched off, the behavior of these cells changed completely: they became more potent at migrating from the intestine to the meninges, the membrane surrounding the brain.

That migration proved to be consequential. Once in the meninges, the dendritic cells promoted protective T cells, a class of immune cells capable of dampening inflammation and tissue damage, and thereby helped reduce the injury in the brain. The picture that emerges is a chain of events running from the dinner plate to the brain’s outer membranes: dietary tryptophan is converted by tnaA-carrying bacteria into indole; indole engages AHR in intestinal dendritic cells; that engagement restrains the cells from migrating and from fostering protective T cells; and the resulting immune balance tilts toward greater brain damage after a stroke. Blocking the receptor breaks the chain at its immunological link and tips the balance back toward protection.

Crucially, the researchers found evidence that this pathway may not be a peculiarity of mice. In a cohort of human patients with ischemic stroke, the ISD team observed that a higher abundance of bacterial TnaA — the gene that enables indole production — was associated with poorer functional outcome. The patient samples for this analysis were provided by collaborating teams led by Fernández-Cadenas in Barcelona and Lorenz Hirt in Lausanne. The human data, while correlational, align with the mouse experiments and suggest that the same microbial machinery could be operating in people, influencing how well patients recover from stroke in the real world.

The study also uncovered a connection to stroke risk factors themselves. Bacteria carrying the tnaA gene and capable of producing indole were more abundant in people with conditions known to raise stroke risk, including obesity and type 2 diabetes. This observation hints at a possible mechanism by which metabolic disease could prime the immune system for a worse response to brain injury, though the researchers are careful to note that much remains to be established about whether the full pathway identified in mice also operates in patients.

The complexity of the work made collaboration essential. The study drew on the Transregional Collaborative Research Centre TRR 355, a research network funded by the German Research Foundation (DFG) that focuses on regulatory T cells. Benakis emphasized that the project required expertise a small group could not have covered alone: the TRR 355 network provided financial support and access to the knowledge of group leaders within the consortium. In addition, the team worked with Michael Zimmermann at EMBL and Michael Gigl at TUM to detect tryptophan metabolites and microbial indole, measurements that are technically challenging because of the low concentrations and complex chemistry involved. It was, as Benakis put it, a real team effort.

Beyond its immediate findings, the study opens a question that could reshape how scientists think about stroke prevention: could changing the gut microbiome, or the metabolites it produces, in healthy individuals help prepare the immune system to respond differently if a stroke occurs? Most stroke research and therapy focuses on the brain itself — clot removal, neuroprotection, rehabilitation — while the systemic immune context in which the injury unfolds has received far less attention as a target. If the gut’s contribution proves as influential in humans as it appears to be in mice, interventions ranging from diet to microbial or metabolic therapies could conceivably be used to tilt the immune system toward a protective configuration before a stroke ever happens, particularly in people at elevated risk. As Delgado Jiménez observed, stroke is usually thought of as an injury restricted to the brain, but the findings show that the gut can help shape the immune response to that injury. Benakis noted that the team still needs to determine whether the mechanism identified in mice also occurs in patients, but the work opens new avenues for investigating whether the gut microbiota could eventually be targeted to improve stroke outcome, including through preventive approaches in those most vulnerable.

Subject of Research: How the gut bacterial metabolite indole influences immune responses and brain damage after stroke

Article Title: How gut bacteria can shape the brain’s response to stroke

Article References: How gut bacteria can shape the brain’s response to stroke. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: stroke, gut microbiota, indole, tryptophan, aryl hydrocarbon receptor, dendritic cells, T cells, meninges, ischemic stroke, tnaA, immune response, LMU

The research began with a deceptively simple observation. Breast cancer patients frequently experience chronic stress disorders alongside disruptions of the gut microbiota, a state known as dysbiosis. Whether these two phenomena merely coexist or actively conspire to worsen outcomes has been unclear. To probe the question, the researchers turned to mouse models in which chronic stress could be induced and its consequences on breast cancer behavior measured. What they found was striking in its specificity: stress did not make the primary tumors grow faster. Instead, it left tumor growth essentially untouched while dramatically enhancing metastasis, particularly to the lungs, and reshaping the immune environment at the metastatic site. The distinction matters enormously, because most cancer therapies are designed to shrink tumors, while metastasis, the process by which cancer cells seed new colonies in distant organs, is what ultimately kills most patients.

Using 16S rDNA sequencing to catalog the gut bacterial communities of stressed and unstressed animals, the team zeroed in on Alistipes putredinis as a key player. This bacterium expanded under chronic stress conditions, and its expansion correlated with the surge in lung metastases. But the microbe itself was only part of the story. A. putredinis is a producer of indole-3-acetic acid, a metabolite generated from the dietary amino acid tryptophan. Targeted tryptophan metabolomics confirmed that stressed animals carried elevated levels of this bacterial product, linking a specific microbial species, a specific biochemical pathway and a specific pathological outcome into a single chain of evidence.

The mechanistic heart of the paper lies in how IAA actually helps cancer cells travel. Working with 4T1 cells, an aggressive mouse breast cancer line commonly used to model metastatic disease, the researchers showed that IAA promotes cell migration through a signaling pathway centered on the aryl hydrocarbon receptor, or AhR. AhR is a ligand-activated transcription factor best known for sensing environmental and dietary chemicals, including many microbial metabolites, and it has increasingly been implicated in cancer biology and immune regulation. According to the study, IAA’s engagement of AhR drives oxidative stress within the cancer cells, and that oxidative burden somehow equips them to migrate more effectively. When the team administered CH223191, a well-characterized pharmacological inhibitor of AhR, the migration of 4T1 cells was suppressed in vitro, and metastasis was inhibited in vivo. In other words, blocking the receptor that IAA activates was enough to sever the link between the bacterial metabolite and the spread of cancer.

Enter baicalin, the compound that gives the study its therapeutic punch. Baicalin has previously been credited with antitumor, antibacterial and microbiota-regulating properties, and it has been explored as a treatment for breast cancer and as a means of preventing metastasis. What remained unexplored, the authors note, was exactly how baicalin’s influence on the gut microbiota might translate into protection against metastatic spread. The new experiments provide an answer that operates on two levels simultaneously. First, baicalin treatment reduced the abundance of A. putredinis in the gut, thinning the ranks of the metabolite-producing culprit. Second, and perhaps more intriguingly, baicalin modulated the tryptophan metabolism of the remaining A. putredinis, suppressing the bacterium’s production of IAA rather than simply killing the organism outright. The result was a double hit: fewer producers and less product.

The downstream consequences for the immune system were equally notable. Baicalin treatment inhibited lung metastasis and increased both the number and the cytotoxicity of CD8-positive T cells in the lungs. These cytotoxic T lymphocytes are the immune system’s primary assassins of tumor cells, and their presence and killing capacity in the lung, the organ where metastatic colonies were forming, suggests that baicalin effectively re-armed local immunity against disseminated cancer cells. The study thus sketches a coherent causal arc: chronic stress reshapes the gut microbiota, the reshaped community floods the host with IAA, IAA acts through AhR to make cancer cells more migratory and to degrade the immune environment at metastatic sites, and baicalin interrupts this cascade at the microbial source while simultaneously restoring the anti-tumor immune response.

To cement the causal role of the microbiota, the researchers deployed fecal microbiota transplantation, a technique that transfers the entire gut microbial community from one set of animals to another. By transplanting microbiota from baicalin-treated animals into untreated recipients, the team could confirm that the protective effects of the drug were genuinely mediated through the gut microbial community rather than through some independent action on the tumor cells themselves. This experimental logic is critical in microbiome research, where correlations between microbial abundance and disease outcomes abound but rigorous demonstrations of causation remain comparatively rare.

Perhaps the most clinically resonant finding comes from the human data. The researchers enrolled 60 breast cancer patients with metastasis at Yulin Red Cross Hospital in Guangxi, China, under an approved ethical protocol with informed written consent. In these patients, those with metastasis and severe depression, a proxy for the chronic stress state modeled in the mice, showed an increased abundance of A. putredinis in their feces and increased concentrations of IAA in their serum. The human correlative data thus mirror the mouse mechanistic data, suggesting that the stress-microbe-metabolite axis identified in the laboratory may also operate in patients. The authors are careful to frame these findings as revealing stress-driven microbiota and metabolite alterations that may facilitate breast cancer metastasis, a phrasing that acknowledges the correlative nature of the human component while emphasizing the mechanistic completeness of the animal work.

The implications of the study extend in several directions at once. For microbiome science, it adds a vivid example of how a psychological state can be transduced, via gut bacteria, into a circulating chemical signal with direct consequences for cancer behavior. The gut-brain axis has been implicated in mood, immunity and neurodegeneration, but a documented pathway from chronic stress through a named bacterial species and a named metabolite to a named signaling receptor in metastasizing cancer cells is an unusually complete chain. For oncology, it raises the possibility that microbial metabolites could serve as biomarkers of metastatic risk in stressed patients, or that microbiota-directed interventions could complement existing therapies. And for pharmacology, the work offers a mechanistic vindication of baicalin, a compound with deep roots in traditional Chinese medicine, by showing that its anti-metastatic effects may depend less on direct toxicity to tumor cells than on a sophisticated ecological intervention in the gut.

Considerable work remains before any of this reaches the clinic. The mouse findings were generated in the 4T1 model, and metastasis biology can differ substantially between mice and humans. The patient cohort, while valuable, demonstrates association rather than causation, and it remains to be seen whether lowering IAA through microbiota manipulation would genuinely reduce metastatic risk in people. Dosing, safety and the long-term ecological consequences of suppressing a common gut commensal all require scrutiny. Still, the study stands as a compelling demonstration that the road from a stressed mind to a spreading cancer may pass through the gut, and that an old herbal molecule, by quieting a single bacterial pathway, can help close it. The research was supported by the National Natural Science Foundation of China and several provincial and institutional funds, and the article is published open access in Microbiome.

Subject of Research: The role of the gut bacterium Alistipes putredinis and its metabolite indole-3-acetic acid in stress-driven breast cancer metastasis and its inhibition by baicalin

Article Title: Pharmacological inhibition of Alistipes putredinis-derived indole-3-acetic acid by baicalin suppresses stress-driven breast cancer metastasis

Article References: Tao, R., Wu, J., Mao, T., Zong, G., Pan, Y., Deng, R., Chen, W., Li, X., Shan, Y., Lu, Y., & Wei, Z. (2026). Pharmacological inhibition of Alistipes putredinis-derived indole-3-acetic acid by baicalin suppresses stress-driven breast cancer metastasis. Microbiome. https://doi.org/10.1186/s40168-026-02519-1

Image Credits: AI Generated

DOI: 10.1186/s40168-026-02519-1

Keywords: breast cancer, metastasis, chronic stress, gut microbiome, Alistipes putredinis, indole-3-acetic acid, baicalin, aryl hydrocarbon receptor, tryptophan metabolism, CD8 T cells, fecal microbiota transplantation, microbiota-gut-brain axis

The Corpus Christi Inner Harbor is no ordinary estuary. Home to the sixth largest port in the United States and ringed by petrochemical and industrial facilities along the Tule Lake Channel, the harbor’s sediments carry a heavy burden of contaminants of concern, including mercury, lead, zinc, polycyclic aromatic hydrocarbons, and polychlorinated biphenyls, commonly known as PCBs. The levels of PCB contamination found there are comparable to those measured in the most heavily industrialized inland stretches of the Houston Ship Channel, a waterway already famous among toxicologists for producing pollution-resistant fish. For killifish living in the Inner Harbor, these dioxin-like compounds represent a powerful and unrelenting selective pressure.

Dioxins, furans, PAHs, and PCBs share a common mode of action that makes them particularly dangerous to developing fish. They activate the aryl hydrocarbon receptor, or AHR, a transcription factor that responds to foreign chemicals and switches on a battery of detoxification genes, including cytochrome P4501A, or CYP1A, a critical enzyme in Phase I metabolism. The AHR pathway is highly conserved across animal taxa, but fish carry multiple copies of the AHR gene, and in teleosts the AHR2 copy is the most functionally important for responding to dioxin-like compounds. Paradoxically, while the pathway exists to detoxify xenobiotics, its chronic activation causes severe developmental malformations, including devastating heart deformities in fish embryos. Experiments in zebrafish have shown that knocking down AHR2 actually protects embryos from dioxin-induced cardiac toxicity, a biological irony that hints at how resistance might evolve.

That hint has been borne out repeatedly in killifish. Atlantic killifish, Fundulus heteroclitus, living near EPA Superfund sites along the Atlantic Coast have independently evolved resistance to persistent pollutants, and genomic studies show that genes in the AHR signaling pathway are recurrent targets of natural selection in these adapted populations. The Gulf killifish, the Atlantic species’ close sister, has followed a similar path in the Houston Ship Channel, where twelve populations have been characterized. Populations closest to the most industrialized section of the channel display strong resistance to PCB-induced cardiac teratogenesis, and many carry a 77-kilobase genomic deletion spanning the AHR1a and AHR2a genes, a deletion that likely entered the species through a recent hybridization event with Atlantic killifish, possibly mediated by accidental human transport of fish or larvae.

The new study, led by Rachel B. Walkup and colleagues at Baylor University, asked whether a similar evolutionary story had unfolded some 200 miles away in the Corpus Christi Inner Harbor. The researchers collected fish from two contaminated sites, Tule Lake and Up River Road, in April 2022, and compared their embryos with two previously characterized Galveston Bay populations: Vince Bayou, an adapted and resistant population from the Houston Ship Channel, and Smith Point, a non-adapted reference population. Because Gulf killifish show high site fidelity and limited gene flow between populations, the geographic separation between the two bays raised a compelling question: had the Corpus Christi fish evolved resistance independently, or did they share ancestry with their adapted Houston cousins?

To find out, the team exposed embryos from all four populations to varying doses of PCB126, a potent model AHR agonist, and scored heart deformities at 144 hours post fertilization. The results were dramatic. Embryos from the Smith Point reference population developed significant cardiac deformities starting at just 5 micrograms per liter, while the Vince Bayou population showed no significant deformities at any tested dose. The two Corpus Christi populations fell squarely in between: significant heart deformities appeared only at 50 micrograms per liter for Up River Road embryos and 100 micrograms per liter for Tule Lake embryos. When the researchers calculated the concentration that caused deformities in half of the embryos, the EC50 values for the Corpus Christi populations were approximately 300 times higher than those of the reference population, placing them at a resistance level comparable to intermediate-high populations from the Houston Ship Channel.

The mechanism behind this resistance appears to involve a blunted AHR pathway. Using an in ovo EROD assay, which measures fluorescent resorufin produced by CYP1A activity in the embryos’ urinary bladders, the researchers found that both Corpus Christi populations had significantly lower basal CYP1A activity than the reference population and reduced maximal inducibility following PCB126 exposure. Notably, basal and maximal CYP1A activity did not differ significantly within any adapted population, indicating a compressed range of pathway responsiveness. Across the Corpus Christi populations and twelve previously characterized Galveston Bay populations, basal and maximal CYP1A activity were strongly linearly correlated, and EC50 values for cardiac deformity were strongly correlated with maximal CYP1A inducibility. This pattern suggests that downregulation of the AHR pathway is the common engine of resistance across all of these adapted populations, even those separated by hundreds of miles of coastline.

Yet the study also uncovered a puzzling wrinkle. While the population-level correlation between CYP1A inducibility and cardiac protection was robust, individual CYP1A activity did not reliably predict whether a given embryo would develop heart deformities. Individual CYP1A responses varied enormously within the Corpus Christi populations, spanning the range observed between the sensitive reference population and the highly resistant Vince Bayou population. To explain this discrepancy, the researchers propose a theoretical model in which cardiac deformity begins once CYP1A activity declines to roughly half of its peak on the descending side of the dose-response curve. Because individual fish within an adapted population sit at different points along a continuum of AHR responsiveness, they reach that toxic threshold at different PCB concentrations, which is why a single CYP1A measurement at one dose cannot predict an individual embryo’s fate. The model also acknowledges other possible contributors, including variation in contaminant uptake, oxidative stress responses, and partial desensitization that uncouples receptor activation from downstream transcription.

The discovery of a second cluster of adapted Gulf killifish populations carries implications well beyond the Texas coast. It demonstrates that similar pollution regimes can drive the evolution of comparable adaptive traits in geographically isolated estuarine populations, reinforcing the emerging view that rapid evolutionary adaptation to toxic pollution is a repeatable and predictable phenomenon. Whether the Corpus Christi resistance arose independently, through shared ancestry, or via gene flow from Houston Ship Channel populations remains an open question that future population genomic and proteomic analyses will need to resolve, particularly since intermediate-high resistant populations in Galveston Bay show resistance despite carrying the introgressed AHR deletion at low frequencies, hinting that additional, possibly AHR-independent mechanisms may be at work. As industrial contamination continues to reshape coastal ecosystems worldwide, the Gulf killifish now stands alongside its Atlantic cousin as a powerful model for evolutionary toxicology, a living record of how wildlife can, at least sometimes, outrun the poisons humans leave behind.

Subject of Research: Evolved pollution tolerance in Gulf killifish populations from the Corpus Christi Inner Harbor, Texas

Article Title: Evolved pollution tolerance in Gulf killifish (Fundulus grandis) from the Corpus Christi Inner Harbor, Texas, USA

Article References: Walkup, R. B., Swearingen, C., Steele, L. R., Greer, K. E., Kim, J., & Matson, C. W. (2026). Evolved pollution tolerance in Gulf killifish (Fundulus grandis) from the Corpus Christi Inner Harbor, Texas, USA. Ecotoxicology, 35(7), Article 164. https://doi.org/10.1007/s10646-026-03144-2

Image Credits: AI Generated

DOI: 10.1007/s10646-026-03144-2

Keywords: Gulf killifish, evolutionary toxicology, PCB resistance, aryl hydrocarbon receptor, CYP1A, Corpus Christi Inner Harbor, cardiac teratogenesis, pollution adaptation, EROD assay, Houston Ship Channel, estuarine contamination, rapid evolution